|
James N. Topper, M.D., Ph.D., is a General Partner at Frazier Healthcare, where he is responsible for investments within the biopharma sector. Dr. Topper joined Frazier Healthcare in 2003 as a Venture Partner and became a General Partner in 2005. Prior to joining Frazier Healthcare, he served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Prior to the merger of COR and Millennium, Dr. Topper served as the Vice President of Biology at COR and was responsible for managing all of its research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR, where he functioned as a clinician, instructor and basic investigator. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. He continues to hold an appointment as a Clinical Assistant Professor of Medicine at Stanford University and as a Cardiology Consultant to the Palo Alto Veterans Administration Hospital. Dr. Topper currently serves on the boards of Amicus Therapeutics, Arête Therapeutics, La Jolla Pharmaceuticals, MacuSight Inc., and Zelos Therapeutics, Inc., and is an observer on the boards of Point Biomedical and Portola Pharmaceuticals. He is also an advisory board member to the Harvard-Partners Center for Genetics and Genomics. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford University School of Medicine in 1991 under the auspices of the Medical Scientist Training Program. | 